All In Biotech

Drug Trial Radar · NCT04259281

A Study of the Safety and Tolerability of GTX-102 in Children With Angelman Syndrome

A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS)

Last checked: Nov 20, 2026Latest source record: Jan 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

74

Actual

Start

Feb 24, 2020

Primary completion

Jan 8, 2025

Study completion Jan 8, 2025

Sponsor

Lead sponsor
Ultragenyx Pharmaceutical IncIndustry
Sponsor type
Industry
First posted
Feb 6, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 4 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to evaluate the safety and tolerability of multiple-ascending doses of GTX-102 administered by intrathecal (IT) injection to participants with Angelman Syndrome (AS).

Conditions

  • Angelman Syndrome

Interventions

  • GTX-102Drug

    antisense oligonucleotide

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events (AEs), Serious AEs (SAEs), Adverse Events of Special Interest (AESIs), AEs Leading to Discontinuation and Severity of AEsTime frame: Up to Day 337

Locations

25 sites in 8 countries. Site status is shown where the registry gives one.

  • UCLA Medical Center

    Los Angeles, California

  • Rady Children's Hospital

    San Diego, California

  • Rare Disease Research

    Atlanta, Georgia

  • Rush University Medical Center

    Chicago, Illinois

  • Boston Children's Hospital

    Boston, Massachusetts

  • Weill Cornell Medicine

    New York, New York

  • Queensland Children's Hospital

    South Brisbane, Australia

  • Austin Health

    Heidelberg, Victoria, Australia

  • The Royal Children's Hospital

    Parkville, Victoria, Australia

  • MAGIC Clinic Ltd

    Calgary, Alberta, Canada

  • British Columbia Children's Hospital

    Vancouver, British Columbia, Canada

  • Children's Hospital of Western Ontario

    London, Ontario, Canada

  • Children's Hospital of Eastern Ontario

    Ottawa, Ontario, Canada

  • McGill University Health Centre

    Montreal, Quebec, Canada

  • Hopital de la Timone

    Marseille, France

  • AP-HP Hopital Necker-Enfants Malades

    Paris, France

  • Universitatsklinikum Hamburg-Eppendorf

    Hamburg, Germany

  • Universitatsklinikum Leipzig

    Leipzig, Saxony, Germany

  • The Edmond and Lily Safra Children's Hospital

    Ramat Gan, Israel

  • Hospital Sant Joan de Deu

    Esplugues de Llobregat, Barcelona, Spain

  • Hospital Universitari Parc Tauli

    Sabadell, Barcelona, Spain

  • Hospital Universitario Puerta de Hierro

    Majadahonda, Madrid, Spain

  • Cambridge University Hospitals

    Cambridge, United Kingdom

  • Great Ormond Street Hospital for Children

    London, United Kingdom

  • Oxford University Hospitals NHS Foundation Trust

    Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.